Alberto Servetto Highlights High Early Censoring Rates in Immunotherapy Studies
Alberto Servetto, Assistant Professor of Oncology at University of Naples Federico II, shared a post on LinkedIn about a paper published on Journal of the National Cancer Institute:
“I am happy and proud to share our recent paper about censoring in trials of immunotherapy in solid cancers, published in JNCI.
Although immunotherapy reshaped the treatment landscape of multiple cancers, methodological criticisms are present in trials that led to their approval.
Censoring data were available in less than 40% of PFS and OS K-M curves
Censoring rates are high particularly in the first months after patients’ enrollment
Censoring was higher in open-label than double-blinded trials.
The work was led by two outstanding young residents, Filippo Vitale and Fabio Salomone.
Thanks to all co-authors for their precious contribution.”
Luigi Formisano, Associate Professor of Medical Oncology at University of Naples Federico II, shared Alberto Servetto’s post, adding:
“Exciting new research from the Oncology team at the University of Naples Federico II!
Grateful to be part of such a passionate and talented team.”
Title: Censoring in trials testing immunotherapy in advanced cancers. A systematic review and a meta-research study
Authors: Filippo Vitale, Fabio Salomone, Massimo Di Maio, Simeone D’Ambrosio, Annarita Avanzo, Fabiana Napolitano, Angela Viggiano, Luigi Liguori, Anna Russo, Maria Carmela Isernia, Lucia Longo, Antonio Santaniello, Luigi Formisano, Roberto Bianco, Alberto Servetto
Read the full article.
More posts featuring Luigi Formisano and Alberto Servetto on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023